Skip to search formSkip to main contentSkip to account menu

zanolimumab

Known as: Anti-CD4 Monoclonal Antibody HuMax, HuMax-CD4 
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
BackgroundHuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a… 
Highly Cited
2017
Highly Cited
2017
The complex signaling networks of the tumor microenvironment that facilitate tumor growth and progression toward metastatic… 
Review
2011
Review
2011
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… 
Highly Cited
2010
Highly Cited
2010
The efficacy and safety of zanolimumab (HuMax‐CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was… 
Review
2008
Highly Cited
2007
Highly Cited
2007
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two… 
2007
2007
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are… 
Highly Cited
2005
Highly Cited
2005
OBJECTIVE Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in… 
2005
2005
A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated… 
Highly Cited
2003
Highly Cited
2003
BACKGROUND Psoriasis is characterized by infiltration with mononuclear cells. Especially activated memory CD4+ T cells are…